

# Mycobacterium tuberculosis, Strain CDC1551, Transposon Mutant Knock-Out Pool 5

Catalog No. NR-15777

For research use only. Not for human use.

## Contributor:

W. R. Bishai, Professor and Co-Director of the Center for Tuberculosis Research, Department of Medicine, Johns Hopkins School of Medicine, Baltimore MD

## Product Description:

Bacteria Classification: *Mycobacteriaceae*; *Mycobacterium*

Species: *Mycobacterium tuberculosis*

Strain: CDC1551 (also referred to as CSU93 or Oshkosh)

Original Source: *Mycobacterium tuberculosis* (*M. tuberculosis*), strain CDC1551 is a clinical isolate that exhibited high levels of infectivity and virulence during a tuberculosis outbreak that occurred in rural Kentucky and Tennessee from 1994 to 1996.<sup>1</sup> In 2002, [TARGET](#) (Tuberculosis Animal Research and Gene Evaluation Taskforce) was formed to enable the modeling of human tuberculosis in multiple animal species using defined protocols and testing defined mutants of *M. tuberculosis*. In addition to animal modeling activities, a library of intragenic transposon mutants has been created and characterized.<sup>2</sup>

Comments: There are 20 transposon mutant knock-out pools available from BEI Resources (NR-15773 to NR-15792) that are companion products to the DeADMAN DNA Microarray (available from BEI Resources as NR-18958). The DeADMAN DNA Microarray is used for identification of genes essential for the survival of a stress condition in an *in vivo* model system infection.<sup>3</sup>

*M. tuberculosis*, strain CDC1551 transposon mutant knock-out pool 5 is reported to be a mixture of 19 genetically defined *M. tuberculosis* transposon mutants described in Table 1. Some of the transposon mutants in knock-out pool 5 are available individually as indicated in Table 1.

## Material Provided:

Each vial contains approximately 1 mL of bacterial culture in Middlebrook 7H9 broth with OADC enrichment containing 100 µg/mL cycloheximide and 20 µg/mL kanamycin.

## Packaging/Storage:

NR-15777 was packaged aseptically, in screw-capped plastic cryovials. The product is provided frozen and should be stored at -60°C or colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended. Freeze-thaw cycles should be avoided.

## Growth Conditions:

### Media:

Middlebrook 7H9 Broth with OADC enrichment containing 100 µg/mL cycloheximide and 20 µg/mL kanamycin

[Middlebrook 7H10](#) Agar with OADC enrichment 100 µg/mL cycloheximide and 20 µg/mL kanamycin

### Incubation:

Temperature: 37°C

Atmosphere: Aerobic

### Propagation:

1. Keep vial frozen until ready for use; thaw slowly.
2. Transfer the entire thawed aliquot into a single tube of broth.
3. Use several drops of the suspension to inoculate an agar slant and/or plate.
4. Incubate the tubes and plate at 37°C for 2 to 4 weeks.

## Citation:

Acknowledgment for publications should read "The following reagent was obtained through the NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH: *Mycobacterium tuberculosis*, Strain CDC1551, Transposon Mutant Knock-Out Pool 5, NR-15777."

## Biosafety Level: 3

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. [Biosafety in Microbiological and Biomedical Laboratories](#), 5th ed. Washington, DC: U.S. Government Printing Office, 2007; see [www.cdc.gov/od/ohs/biosfty/bmbl5/bmbl5toc.htm](http://www.cdc.gov/od/ohs/biosfty/bmbl5/bmbl5toc.htm).

## Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at [www.beiresources.org](http://www.beiresources.org).

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government make any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI

Resources are not liable for damages arising from the misidentification or misrepresentation of products.

### Use Restrictions:

**This material is distributed for internal research, non-commercial purposes only.** This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

### References:

1. Valway, S. E., et al. "An Outbreak Involving Extensive Transmission of a Virulent Strain of *Mycobacterium tuberculosis*." *N. Engl. J. Med.* 338 (1998): 633-639. PubMed: 9486991.
2. Lamichhane, G., et al. "A Postgenomic Method for Predicting Essential Genes at Subsaturating Levels of Mutagenesis: Application to *Mycobacterium*

*tuberculosis*." *Proc. Natl. Acad. Sci. U. S. A.* 100 (2003): 7213-7218. PubMed: 12775759.

3. Lamichhane, G., S. Tyagi and W. R. Bishai. "Designer Arrays for Defined Mutant Analysis to Detect Genes Essential for Survival of *Mycobacterium tuberculosis* in Mouse Lungs." *Infect. Immun.* 73 (2005): 2533-2540. PubMed: 15784600.
4. Cole, S. T., et al. "Deciphering the Biology of *Mycobacterium tuberculosis* from the Complete Genome Sequence." *Nature* 393 (1998): 537-544. PubMed: 9634230. Erratum in: *Nature* 396 (1998): 190-198.

ATCC® is a trademark of the American Type Culture Collection.



**Table 1. Transposon Mutant Members of Knock-Out Pool 5**

Description of Transposon Knock-Out Mutant	Strain CDC1551 Gene	Strain H37Rv Gene <sup>1</sup>	BEI Resources Product Number <sup>2</sup>
PROBABLE ENOYL-CoA HYDRATASE ECHA1 (ENOYL HYDRASE) (UNSATURATED ACYL-CoA HYDRATASE) (CROTONASE)	MT0232	Rv0222	NA
PROBABLE CONSERVED LIPOPROTEIN LPPO	MT2347	Rv2290	NA
CONSERVED HYPOTHETICAL PROTEIN	MT3093	Rv3013	NR-15670
CADMIUM INDUCIBLE PROTEIN CADI	MT2719	Rv2641	NA
CONSERVED HYPOTHETICAL PROTEIN	MT2191	Rv2133c	NR-15066
PROBABLE ALANINE RICH HYDROLASE	MT2835	Rv2765	NR-15067
CONSERVED HYPOTHETICAL PROTEIN	MT1970	Rv1919c	NA
PROBABLE AMMONIUM-TRANSPORT INTEGRAL MEMBRANE PROTEIN AMT	MT2988	Rv2920c	NA
PROBABLE ESTERASE	MT0230	Rv0220	NR-18060
PROBABLE GLUCOSE-6-PHOSPHATE 1-DEHYDROGENASE ZWF1 (G6PD)	MT1153	Rv1121	NA
CONSERVED HYPOTHETICAL PROTEIN	MT2638	Rv2562	NR-15071
PROBABLE FATTY-ACID-CoA LIGASE FADD9 (FATTY-ACID-CoA SYNTHETASE) (FATTY-ACID-CoA SYNTHASE)	MT2667	Rv2590	NA
PROBABLE CONSERVED MCE ASSOCIATED TRANSMEMBRANE PROTEIN	MT0185	Rv0176	NA
PROBABLE PRECORRIN-4 C11-METHYLTRANSFERASE	MT2131	Rv2071c	NR-15073
PROBABLE CYSTATHIONINE BETA-SYNTHASE CBS (SERINE SULFHYDRASE) (BETA-THIONASE) (HEMOPROTEIN H-450)	MT1108	Rv1077	NA
CONSERVED HYPOTHETICAL PROTEIN	MT1928	Rv1879	NA
PROBABLE CONSERVED INTEGRAL MEMBRANE TRANSPORT PROTEIN	MT1710	Rv1672c	NR-15074
CONSERVED HYPOTHETICAL PROTEIN	MT1534	Rv1489	NR-15075
PE-PGRS FAMILY PROTEIN	MT1866	Rv1818c	NA

<sup>1</sup>Rv\* – In some cases there is no *M. tuberculosis*, strain H37Rv homologue to the *M. tuberculosis*, strain CDC1551 gene

<sup>2</sup>NA – Individual transposon mutant not available from BEI Resources but may be available from [TARGET](#)